No Data
Citi: Rated innovent bio (01801) as a 'buy', with a target price of 55 Hong Kong dollars.
Citi believes that innovent bio's strong sales performance and overseas clinical progress will sustainably restore investor confidence.
Innovent Biologics Terminates Share Subscription Agreement With Lostrancos Ventures
Net inflow of nearly 3.3 billion Hong Kong dollars in southbound funds on November 4: Increased positions in Xiaomi Corporation and Innovent Bio, outflow from Semiconductor Manufacturing International Corporation and CNOOC.
①The southbound funds had a daily turnover of approximately 55.3 billion Hong Kong dollars. Which individual stocks continued to receive inflows of funds? ②Xiaomi Group received over 0.4 billion Hong Kong dollars in inflows. How did the stock price perform?
Haitong Securities 24Q3 Fund Hong Kong Stock Holdings Analysis: Increase consumer holdings, decrease energy and materials holdings.
24Q3 public funds did not make significant changes to their investment strategy in the Hong Kong stock market, continuing to reduce positions in high dividend sectors, especially reducing positions in energy and materials which had significant gains in the previous period. They mainly increased positions in internet-related optional consumer sectors, and also slightly increased positions in manufacturing sectors like autos.
The opening stock price surged by more than 14%, innovent bio (01801) returned to the main investment theme of innovation-driven growth.
On the morning of November 4th, innovent bio opened with a sharp rise, with the stock price reaching a high of 40.05 Hong Kong dollars, a 14.27% increase. The strong market sentiment and market buying orders reflect investors' approval of the company's above decisions.
CICC: Maintains the "outperform" rating on Innovent Bio (01801), with the target price raised to HK$61.
Jianyin International has raised its total revenue forecast for innovent bio for 2024-2026 by 4%, to 8.9 billion yuan/11.8 billion yuan/16.5 billion yuan.
No Data
No Data
